Drug Development

Our scientific breakthrough enables the development of both small- and large-molecule therapeutics tailored to address specific unmet needs of several major disease areas in dermatology, respiratory, gastrointestinal conditions, fibrotic diseases, chronic inflammation disorders and neuroinflammation.

Lead Program Small Molecules

Small molecule MCS111/2-XXX with currently two lead program series (MCS111XX, MCS112XX) with expected excellent translation to clinical success in humans targeting major diseases areas in dermatology, (e.g. chronic spontaneous urticaria), rare disease mastocytosis, respiratory (COPD, asthma), gastrointestinal diseases (food allergy, IBS, IBD), fibrotic diseases (pulmonary fibrosis, liver fibrosis), and systemic chronic inflammation disorders (e.g. MCAS, fibromyalgia, IBS, long covid, chronic lyme).

Follow-Up Program mAb

MCS20-XXX Series designed to enable enhanced mast cell silencing and depletion for the accelerated depletion of accumulated activated mast cells in a controlled manner to meet specific disease needs, for example, in fibrotic diseases, COPD and rare disease systemic mastocytosis.

Follow-Up Program Small Molecules Neuroinflammation 

MCS12-XXX Series targeting mast cells in neuroinflammation in diseases such as ASD (autism spectrum disorders), ALS, severe dengue, stroke, alzheimer’s, disease, and mood disorders.